Table 3 Respiratory care practices of the study population
Respiratory therapy | ≤750 g (n = 25) | 751-1000 g(n = 158) | 1001-1250 g(n = 369) | 1251-1500 g(n = 507) | Total(n = 1059) | χ2 | P | P value for trend |
|---|---|---|---|---|---|---|---|---|
HFV(n，%) | 13(52.0%) | 46(29.1%) | 68(18.4%) | 42(8.0%) | 169(15.7%) | 49.734 | 0.000 | 0.000 |
CMV(n，%) | 12(48.0%) | 81(51.3%) | 128(34.7%) | 117(23.0%) | 338(31.9%) | 49.734 | 0.000 | 0.000 |
NHFO(n，%) | 0(0.0) | 6(3.8%) | 4(1.1%) | 5(1.0%) | 15(1.4%) | 7.738 | 0.052 | 0.129 |
BIPAP(n，%) | 8(32.0%) | 57(36.1%) | 98(26.6%) | 60(12.0%) | 223(21.1%) | 55.900 | 0.000 | 0.000 |
CPAP(n，%) | 9(36.0%) | 95(60.1%) | 241(65.3%) | 288(57.0%) | 633(59.8%) | 12.450 | 0.006 | 0.835 |
NIPPV(n，%) | 4(16.0%) | 30(19.0%) | 75(20.3%) | 58(11.0%) | 167(15.8%) | 14.154 | 0.003 | 0.020 |
HHFNC(n，%) | 7(28.0%) | 62(39.2%) | 122(33.1%) | 118(23.0%) | 309(29.2%) | 19.004 | 0.000 | 0.004 |
Nasal catheter(n，%) | 8(32.0%) | 61(38.6%) | 166(45.0%) | 185(36.0%) | 420(39.7%) | 9.191 | 0.066 | 0.889 |
Nose / face mask(n，%) | 1(4.0%) | 20(12.7%) | 57(15.5%) | 75(15.0%) | 173(16.3%) | 6.700 | 0.082 | 0.002 |
PS(n，%) | 16(64.0%) | 102(64.6%) | 200(54.2%) | 218(43.0%) | 536(50.6%) | 27.744 | 0.000 | 0.000 |
Caffeine(n，%) | 19(76.0%) | 121(76.6%) | 256(69.4%) | 292(58.0%) | 688(65.0%) | 25.966 | 0.000 | 0.000 |
Aerosol Inhalation (n，%) | 7(28.0%) | 54(34.8%) | 82(22.2%) | 64(13.0%) | 207(19.6%) | 40.702 | 0.000 | 0.000 |